Sweetbread Mushroom

Metadata

Regulatory Status

United States

• C. prunulus as food/supplement: Not marketed as a dietary supplement or functional food in the US. Not GRAS. Not commonly found in American markets.
• Pleuromutilin-derived drugs (FDA-approved):
  • Lefamulin (Xenleta): FDA-approved August 19, 2019, for the treatment of community-acquired bacterial pneumonia (CABP) in adults. First systemic pleuromutilin antibiotic for human use. Available as IV and oral formulations.
  • Retapamulin (Altabax): FDA-approved 2007 for topical treatment of impetigo and secondarily infected traumatic lesions caused by susceptible strains of Staphylococcus aureus (MSSA) and Streptococcus pyogenes.

European Union

• C. prunulus as food: Widely consumed as a traditional edible mushroom in central and western Europe, particularly in France, Italy, and Germany. Long foraging history. Not subject to novel food regulation.
• Lefamulin: EMA marketing authorization for CABP.
• Retapamulin: Authorized in the EU for topical skin infection treatment.
• Tiamulin and valnemulin: Approved for veterinary use (swine and poultry) in the EU.

Veterinary Regulatory Status (Global)

• Tiamulin (Tiamutin): Approved in 1979. Used worldwide for treatment and prevention of swine dysentery (Brachyspira hyodysenteriae), swine enzootic pneumonia (Mycoplasma hyopneumoniae), and poultry mycoplasmosis.
• Valnemulin (Econor): Approved in 1999 for swine dysentery and ileitis.

China and East Asia

• C. prunulus: Not a traditional medicinal or culinary mushroom in Chinese or Japanese pharmacopeias. The genus is recognized in mycological literature but not in therapeutic traditions.

Conditions & Indications

Primary: Antimicrobial Activity via Pleuromutilin Derivatives (Genus-Level)

• Community-acquired bacterial pneumonia (CABP): Lefamulin is FDA-approved for adult CABP, demonstrating non-inferiority to moxifloxacin in two Phase 3 trials (LEAP 1, LEAP 2). Active against Streptococcus pneumoniae (including multidrug-resistant strains), Staphylococcus aureus (MSSA), Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila.
• Topical skin infections: Retapamulin is approved for impetigo and secondarily infected skin lesions. Active against S. aureus (MSSA) and S. pyogenes.
• Veterinary infections: Tiamulin and valnemulin treat swine dysentery, enzootic pneumonia, and poultry mycoplasmosis.

Secondary: MRSA and Resistant Organism Activity (Research Stage)

• MRSA activity: Pleuromutilin derivatives demonstrate in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA). Novel derivatives are under active development specifically targeting MRSA and other resistant Gram-positive pathogens. Click chemistry approaches have generated pleuromutilin-phenyl sulfide conjugates with enhanced anti-MRSA activity.
• Vancomycin-resistant enterococci (VRE): Some pleuromutilin derivatives show activity against VRE isolates in vitro.

Emerging/Preclinical (C. prunulus Specifically)

• Antimicrobial properties of crude extracts: Preliminary studies suggest C. prunulus extracts possess antimicrobial activity, consistent with the presence of pleuromutilin biosynthetic genes. Specific antimicrobial spectrum and potency of crude extracts are poorly characterized. [NEEDS-RESEARCH]
• Antifungal properties: Reported in preliminary studies but not well characterized. [NEEDS-RESEARCH]
• Antioxidant activity: Phenolic compounds in C. prunulus are expected to provide antioxidant capacity, consistent with other edible mushroom species, but specific data for this species are sparse. [NEEDS-RESEARCH]
• Immunomodulatory potential: As with many edible mushrooms containing polysaccharides and ergosterol, immunomodulatory potential is plausible but has not been specifically investigated for C. prunulus. [NEEDS-RESEARCH]

Mechanism of Action

Primary Mechanisms

1. Pleuromutilin: Inhibition of bacterial protein synthesis at the peptidyl transferase center (PTC): Pleuromutilin and its derivatives bind to the central part of domain V of the 23S rRNA within the 50S ribosomal subunit, specifically at the peptidyl transferase center (PTC) where peptide bond formation occurs. The tricyclic mutilin core (ring system A/B/C) occupies the A-site of the PTC, while the C-14 glycolic acid ester side chain extends into the P-site. This dual-site binding prevents the correct positioning of the 3’-CCA ends of both aminoacyl-tRNA (A-site) and peptidyl-tRNA (P-site), thereby blocking peptide bond formation. The binding involves extensive hydrogen bonding and hydrophobic interactions with 23S rRNA nucleotides including U2506, G2061, A2503, U2585, and C2452.

2. Selectivity for bacterial over eukaryotic ribosomes: Pleuromutilins exhibit high selectivity for bacterial 70S ribosomes over eukaryotic 80S ribosomes, despite the conservation of the peptidyl transferase center across species. Key differences in rRNA nucleotide sequences at the PTC periphery, along with subtle structural distinctions between bacterial and eukaryotic ribosomal proteins, account for this selectivity. This selectivity provides the therapeutic index necessary for clinical use.

3. Minimal cross-resistance with other antibiotic classes: Because pleuromutilins bind at a unique site on the 50S subunit — overlapping with but distinct from the binding sites of macrolides, lincosamides, streptogramins, chloramphenicol, and oxazolidinones — they exhibit minimal cross-resistance with these antibiotic classes. Resistance to pleuromutilins remains rare and typically involves mutations in 23S rRNA (G2032A, C2055A) or ribosomal protein L3, or the acquisition of cfr methyltransferase genes that modify A2503.

Pleuromutilin Biosynthesis in Clitopilus Species

4. Seven-gene biosynthetic cluster: The pleuromutilin biosynthetic pathway in Clitopilus passeckerianus involves a seven-gene cluster encoding:
   • Pl-ggs: Geranylgeranyl diphosphate (GGPP) synthase (produces the C20 isoprenoid precursor)
   • Pl-cyc: Bifunctional diterpene synthase/cyclase (cyclizes GGPP to 3-deoxo-11-dehydroxymutilin, the first tricyclic intermediate)
   • Pl-p450-1, Pl-p450-2, Pl-p450-3: Three cytochrome P450 enzymes (introduce hydroxyl groups at C-11 and C-3, and perform additional oxidations)
   • Pl-sdr: Short-chain dehydrogenase/reductase
   • Pl-atf: Acetyltransferase (installs the C-14 acetyl side chain in the final step) This gene cluster has been successfully expressed in Aspergillus oryzae, achieving a 2,106% increase in production over the native organism, demonstrating the feasibility of heterologous production.

Secondary Mechanisms

• Trans-2-nonenal: The characteristic flour/meal-like odor of C. prunulus (origin of the common name “the miller”) is attributed to trans-2-nonenal, present at 17 micrograms per gram of crushed tissue. Trans-2-nonenal is an aldehyde that has been studied for antimicrobial properties in other contexts but its contribution to C. prunulus bioactivity is not established.
• 1-Octen-3-ol: A common mushroom volatile (“mushroom alcohol”) with documented antifungal activity. In C. prunulus, 1-octen-3-ol serves as a chemical defense against herbivory (effective repellent against banana slugs, Ariolimax columbianus).

Clinical Evidence Summary

Pleuromutilin-Derived Drug Clinical Trials

C. prunulus-Specific Evidence

No clinical trials. No controlled preclinical studies specifically evaluating therapeutic properties of C. prunulus extracts have been published in indexed journals. The evidence base for this species consists of mycological characterization, chemical ecology studies, and the genus-level connection to pleuromutilin production.

Evidence Limitations

• Genus vs. species conflation: The pharmacological significance of Clitopilus prunulus rests primarily on its genus-level relationship to the pleuromutilin-producing species C. passeckerianus. While C. prunulus has been confirmed to harbor pleuromutilin biosynthetic genes, the quantity of pleuromutilin produced by C. prunulus fruiting bodies has not been well quantified. Consuming C. prunulus as food is not equivalent to receiving clinically meaningful antibiotic therapy.
• No direct therapeutic evidence for the mushroom: All clinical evidence pertains to semi-synthetic pharmaceutical derivatives (lefamulin, retapamulin, tiamulin, valnemulin), not to crude mushroom extracts or preparations.
• Sparse bioactivity characterization: Beyond the genus-level antibiotic connection, C. prunulus has received minimal attention for its own bioactive properties (antioxidant, immunomodulatory, etc.) compared to other edible mushrooms.
• Misidentification risk as safety concern: C. prunulus closely resembles toxic Clitocybe species (particularly C. rivulosa and C. dealbata, which contain muscarine), making field identification a safety-critical skill. The pink spore print of C. prunulus (vs. white in Clitocybe) is the primary distinguishing feature.

Safety Profile

General Assessment

Clitopilus prunulus is a well-regarded edible mushroom with a long history of safe culinary use across Europe. No significant toxicity has been associated with consumption of properly identified specimens. The primary safety concern is misidentification with toxic look-alikes rather than intrinsic toxicity of the species itself.

Contraindications

• Mushroom allergy: Persons with known allergy to mushrooms should avoid consumption.
• Identification uncertainty: If there is any doubt about identification, do not consume. Toxic look-alikes include Clitocybe rivulosa and C. dealbata (muscarine-containing, potentially fatal), and some white Entoloma species (gastrointestinal toxins).
• Pregnancy and lactation: No safety data for concentrated extracts. Culinary consumption is presumed safe based on traditional European use.

Drug Interactions

No drug interactions have been documented for consumption of C. prunulus as a food. The pleuromutilin content in the fruiting body is not expected to reach pharmacologically active antimicrobial concentrations through dietary consumption.

For pharmaceutical pleuromutilin derivatives (lefamulin):

• CYP3A4 substrates (lefamulin is a moderate CYP3A4 inhibitor)
• QT-prolonging drugs (lefamulin causes mild QTc prolongation)
• P-glycoprotein substrates

Side Effects

• As food: No significant adverse effects reported from culinary consumption of properly identified specimens.
• Lefamulin (pharmaceutical derivative): Diarrhea (12%), nausea (5%), injection site reactions (IV formulation), hepatic enzyme elevation. QTc prolongation (generally mild, mean 12 ms).

Toxicology

• C. prunulus: No intrinsic toxicity documented. Considered safe when properly identified and cooked.
• Misidentification hazard: This is the primary safety risk. Clitocybe rivulosa and C. dealbata contain muscarine and can cause SLUDGE syndrome (Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis) progressing to bradycardia, bronchospasm, and potentially death. The pink spore print of C. prunulus and the decurrent gill morphology help distinguish it from Clitocybe species, but expert identification is recommended for inexperienced foragers.
• Lefamulin toxicology: Embryo-fetal toxicity in animal studies (contraindicated in pregnancy). Hepatotoxicity risk at supratherapeutic doses.

Clinical Dosage

Culinary Use (Food)

• Fresh fruiting body: Consumed in European cuisine, particularly in France and Italy. Typically 50—150 g fresh weight per serving, sauteed, in omelets, or added to stews and pasta dishes.
• Characteristic use: Valued for its pleasant taste and distinctive flour/meal-like aroma. Often prepared simply to showcase its mild, sweet flavor.
• Identification requirement: Only specimens positively identified by experienced foragers should be consumed, given the dangerous look-alikes.

Pharmaceutical Pleuromutilin Derivatives (Prescribed Medications)

• Lefamulin (Xenleta):
  • IV: 150 mg every 12 hours, infused over 60 minutes
  • Oral: 600 mg every 12 hours
  • Duration: 5—7 days for CABP
• Retapamulin (Altabax):
  • Topical: 1% ointment applied twice daily for 5 days to affected skin area (maximum 100 cm2 total area in adults)
• Tiamulin (veterinary):
  • Swine: 8.8 mg/kg/day in feed or water for 5—7 days
• Valnemulin (veterinary):
  • Swine: 3—4 mg/kg/day in feed

No Established Medicinal Mushroom Dose

No evidence-based dosing exists for C. prunulus as a medicinal mushroom product. The pleuromutilin content of fruiting bodies is not sufficient to achieve antimicrobial therapeutic concentrations through dietary consumption. The pharmaceutical value of the pleuromutilin class is realized through semi-synthetic derivatives manufactured under controlled conditions, not through mushroom consumption.

Sources

• Kavanagh F, Hervey A, Robbins WJ. Antibiotic substances from basidiomycetes: VIII. Pleurotus mutilus (Fr.) Sacc. and Pleurotus passeckerianus Pilat. Proc Natl Acad Sci U S A. 1951;37(9):570-574
• Bailey AM, Alberti F, Kilaru S, et al. Identification and manipulation of the pleuromutilin gene cluster from Clitopilus passeckerianus for increased rapid antibiotic production. Sci Rep. 2016;6:25202
• Paukner S, Riedl R. Pleuromutilins: Potent Drugs for Resistant Bugs—Mode of Action and Resistance. Cold Spring Harb Perspect Med. 2017;7(1):a027110
• Alexander E, Goldberg L, Das AF, et al. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial. JAMA. 2019;322(17):1661-1671
• File TM Jr, Goldberg L, Das A, et al. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) trial. Clin Infect Dis. 2019;69(11):1856-1867
• Fazakerley NJ, Helm MD, Procter DJ. Total synthesis of (+)-pleuromutilin. Chemistry. 2013;19(21):6718-6723
• Kilaru S, Collins CM, Hartley AJ, et al. Investigating pleuromutilin-producing Clitopilus species and related basidiomycetes. FEMS Microbiol Lett. 2009;297(1):24-29
• Alberti F, Kaleem S, Sherber B, Bailey AM, Foster GD. Genome Assembly and Genetic Traits of the Pleuromutilin-Producer Clitopilus passeckerianus DSM1602. J Fungi (Basel). 2022;8(8):862
• Novak R. Are pleuromutilin antibiotics finally fit for human use? Ann N Y Acad Sci. 2011;1241:71-81
• Yan K, Madden L, Choudhry AE, et al. Biochemical Characterization of the Interactions of the Novel Pleuromutilin Derivative Retapamulin with Bacterial Ribosomes. Antimicrob Agents Chemother. 2006;50(11):3875-3881
• Wen C, Ma J, Yu Y, et al. Overexpression of Geranylgeranyl Diphosphate Synthase and Cyclase Enhances Pleuromutilin Production in Clitopilus Passeckerianus T6. Biotechnol J. 2025;20(1):e2500004

Connections

• Antibiotic-producing mushrooms: Clitopilus prunulus and its genus represent the most pharmaceutically significant antibiotic-producing mushroom lineage, rivaling the historical importance of Penicillium molds. The development of lefamulin in 2019 — the first new systemic antibiotic class approved for human use in nearly two decades — underscores the continued relevance of fungal natural products in combating antimicrobial resistance. This contrasts with the immunomodulatory beta-glucan paradigm that characterizes most medicinal mushrooms in this reference (e.g., Turkey Tail PSK/PSP, Shiitake lentinan, Maitake D-fraction).
• Natural product drug development pipeline: The path from the 1951 discovery of pleuromutilin in Pleurotus mutilus (now reclassified as Clitopilus passeckerianus) to the 2019 FDA approval of lefamulin represents a 68-year development arc — illustrating both the enormous pharmaceutical potential and the protracted timelines of natural product drug development. This trajectory parallels the ongoing development of psilocybin-based therapeutics from Psilocybe species.
• Antimicrobial resistance context: The pleuromutilin class is particularly significant in the context of antimicrobial resistance (AMR). With activity against MRSA and other resistant pathogens, and minimal cross-resistance with existing antibiotic classes, pleuromutilins address a critical unmet medical need. The continued discovery of novel pleuromutilin derivatives from Clitopilus species and through semi-synthetic chemistry represents an active research frontier.
• Edible mushroom with hidden pharmaceutical value: The case of C. prunulus illustrates how culinary mushrooms may harbor biosynthetic capabilities of profound pharmaceutical significance. The miller is consumed primarily for its pleasant taste and aroma, with no traditional medicinal attribution, yet its genus produces compounds that save human lives. This parallels the discovery of penicillin from a common bread mold and reinforces the case for systematic bioprospecting of fungal biodiversity.
• Comparison with Oyster Mushroom: The original pleuromutilin was isolated from species then classified in Pleurotus (oyster mushroom genus), though the producing species are now reclassified in Clitopilus. The common name “pleuromutilin” preserves this historical connection to Oyster Mushroom. Both genera belong to the broader Agaricales and produce bioactive compounds, though their pharmacological profiles are entirely different (antimicrobial vs. immunomodulatory/hypocholesterolemic).